Highlights
- The Mediterranean diet (MD) demonstrated both noninferiority and statistical superiority to traditional dietary advice (TDA) in reducing IBS symptom severity.
- 62% of participants on the MD achieved a clinically significant response (≥50-point reduction in IBS-SSS) compared to 42% in the TDA group.
- The MD group saw a mean reduction of 101.2 points in the IBS Symptom Severity Scale, significantly outperforming the -64.5 points observed with TDA.
- The Mediterranean diet offers a more nutrient-dense and less restrictive alternative to the Low FODMAP diet, potentially improving long-term adherence and gut microbiome health.
Background: The Challenge of IBS Nutrition
Irritable Bowel Syndrome (IBS) remains one of the most common functional gastrointestinal disorders worldwide, significantly impacting quality of life and healthcare resource utilization. For years, dietary intervention has been a cornerstone of management, yet the optimal first-line approach remains a subject of clinical debate. Current societal guidelines, including those from the British Society of Gastroenterology and the American College of Gastroenterology, typically recommend Traditional Dietary Advice (TDA)—which focuses on meal patterns, hydration, and the moderation of caffeine, alcohol, and spicy foods—as the first-line therapy.
When TDA fails, clinicians often pivot to the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet. While efficacious, the Low FODMAP diet is notoriously cumbersome, highly restrictive, and requires intensive dietetic support to avoid nutritional deficiencies and potentially deleterious shifts in the gut microbiota. There is an urgent clinical need for an evidence-based dietary intervention that is both effective and sustainable. The Mediterranean diet (MD), characterized by high intakes of fruits, vegetables, whole grains, and healthy fats, has long been lauded for its cardiovascular and metabolic benefits. However, its high fiber and prebiotic content historically caused hesitation among clinicians treating IBS patients. Recent pilot studies challenged this hesitation, leading to the randomized clinical trial conducted by Bamidele and colleagues.
Study Design and Methodology
The study, published in the Annals of Internal Medicine (NCT05985018), was a randomized noninferiority clinical trial conducted via an online virtual platform to maximize recruitment and ecological validity across the United Kingdom. A total of 139 adults meeting the Rome IV criteria for IBS were enrolled. These participants represented the spectrum of IBS subtypes (IBS-C, IBS-D, and IBS-M) and had a baseline IBS Symptom Severity Scale (IBS-SSS) score of at least 75.
Participants were randomized into two groups for a 6-week intervention period:
1. The Mediterranean Diet (MD) Group (n = 68)
This group followed a diet rich in vegetables, fruits, legumes, nuts, seeds, whole grains, and olive oil, with moderate consumption of fish and poultry, and limited red meat and ultra-processed foods.
2. Traditional Dietary Advice (TDA) Group (n = 71)
This group followed standard first-line advice, which included eating regular meals, drinking adequate fluids, and limiting known triggers like caffeine, alcohol, and high-fat foods.
The primary endpoint was the proportion of patients achieving a clinical response, defined as a reduction of 50 points or more on the IBS-SSS. Secondary endpoints included absolute changes in IBS-SSS, psychological health (anxiety and depression scales), somatic symptom reporting, quality of life (IBS-QOL), and diet satisfaction. Adherence was measured using the Mediterranean Diet Adherence Screener (MEDAS).
Key Findings: Beyond Noninferiority
The results of the modified intention-to-treat analysis were striking. Not only did the Mediterranean diet meet the criteria for noninferiority, but it also demonstrated statistical superiority over traditional dietary advice. In the MD group, 62% (95% CI, 50% to 73%) of participants achieved a clinical response. In contrast, only 42% (CI, 31% to 55%) of the TDA group reached the same threshold. This represents a 20-percentage point difference favoring the Mediterranean diet (P = 0.017).
When examining the magnitude of symptom reduction, the MD group experienced a mean decrease in IBS-SSS of 101.2 points, compared to a 64.5-point decrease in the TDA group. The difference between the groups (-36.7 points) was statistically significant (P = 0.034). Furthermore, adherence to the Mediterranean diet significantly increased in the intervention group as measured by the MEDAS score (P < 0.001), suggesting that the diet was not only effective but also adoptable by the study population.
Interestingly, while symptom severity improved significantly more in the MD group, secondary outcomes such as mood, somatic symptoms, and quality of life showed improvements in both groups without statistically significant differences between them. This suggests that while MD is superior for physical symptom control, the psychological benefits of dietary intervention may be more generalized.
Clinical Interpretation and Biological Plausibility
The superiority of the Mediterranean diet in this trial is a paradigm-shifting finding. For decades, the high fiber content of the MD—specifically from legumes and certain vegetables—was thought to potentially exacerbate symptoms of bloating and gas in IBS patients due to fermentation. However, this study suggests that the holistic profile of the MD may counteract these effects. Several mechanisms may explain these results:
1. Anti-inflammatory Properties
The MD is rich in polyphenols and omega-3 fatty acids, which may reduce low-grade mucosal inflammation often observed in IBS patients.
2. Microbiome Modulation
Unlike the Low FODMAP diet, which can reduce the abundance of beneficial Bifidobacteria, the MD promotes a diverse and stable gut microbiome, which is essential for long-term gut health and intestinal barrier integrity.
3. Visceral Hypersensitivity
The nutrient density of the MD may play a role in modulating the gut-brain axis, potentially reducing the visceral hypersensitivity that characterizes IBS.
Expert Commentary
Medical experts note that these findings could simplify the dietary management of IBS. If the Mediterranean diet is established as a first-line option, it provides a healthier, more balanced, and less restrictive alternative to current protocols. Clinicians can now recommend a diet that not only addresses gastrointestinal symptoms but also provides established cardiovascular and metabolic protection.
However, it is important to note the study’s limitations. The intervention lasted only 6 weeks, leaving questions about long-term sustainability and symptom control. Furthermore, the trial was conducted online, which, while practical, may involve a more self-motivated patient population than those seen in general clinical practice. Future research should focus on long-term follow-up and the potential synergistic effects of combining MD with other lifestyle interventions.
Conclusion
The Bamidele et al. trial provides high-quality evidence that the Mediterranean diet is a potent intervention for Irritable Bowel Syndrome. By achieving a 62% response rate and showing superiority over traditional advice, the MD earns its place as a primary dietary strategy. For clinicians, this means a shift away from purely restrictive models toward a more inclusive, nutrient-dense approach that benefits both the gut and the patient’s overall health.
Funding and ClinicalTrials.gov
This study was supported by various academic and clinical research funds in the United Kingdom. ClinicalTrials.gov Identifier: NCT05985018.
References
1. Bamidele JO, Brownlow GM, Flack RM, Buckle RL, Shaw CC, Shiha MG, Aziz I. The Mediterranean Diet for Irritable Bowel Syndrome : A Randomized Clinical Trial. Ann Intern Med. 2025 Dec;178(12):1709-1717. doi: 10.7326/ANNALS-25-01519.
2. Ford AC, et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021.
3. Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527.